In simple terms, what Alkermes plc (NASDAQ: ALKS )
is attempting to do is not easy. Few companies manage to successfully
transition from being a licensor of drug formulation technologies to a
proprietary drug developer and likewise few independent biotechs
successfully take on the challenges of developing drugs for
difficult-to-treat conditions like schizophrenia and depression.
Alkermes has strong technology and intellectual property in its favor,
though, and I for one would not underestimate the long-term potential.
Continue here:
Is Alkermes plc Stock Undervalued?
No comments:
Post a Comment